In this double-blind, randomized study the efficacy of the ergoloid compounds, co-dergocrine mesylate and nicergoline, in the rehabilitation of patients with ischaemic stroke was investigated. A group of 30 patients was treated daily with 60 mg nicergoline, orally, and a second group of 27 patients was given 1.8 – 6 mg co-dergocrine mesylate, orally or intramuscularly, daily (depending on the time since the initial ischaemic insult) for 6 months. Outcome measures included: motoricity index (limb function); Sandoz Clinical Assessment Geriatric (SCAG) scale; psychometric tests to assess functions such as attention, psychomotor performance, perception and sensory and short-term memory; conventional and computerized electroencephalography; and P300 and reaction time measures. The results showed improvements in some aspects such as limb function (P < 0.05), SCAG score (P < 0.01) and some electrophysiological parameters (P < 0.01) after treatment with both drugs. Though statistically significant most of the changes were not large. The efficacy of both drugs was qualitatively similar. The quantitative difference in some aspects in favour of nicergoline could be attributed to differences in the mechanisms of action of the two drugs, although it is also possible that the difference may reflect the dosages used. Nootropic drugs may induce a condition that facilitates the effects of cognitive training.
GlaeskeG: Arzneimittel zur Behandlung von Hirnleistungsstörungen in Alter. Dtsch Apoth Z1985; 125: 1008–1009.
2.
BattagliaA, JoriC, DubiniA: Clinical usefulness of nicergoline in senile mental impairment. The Third Congress of the International Psychogeriatric Association. Chicago 28 – 31 August, 1987.
3.
GoodwinJS, GoodwinJM: The tomato effect: Rejection of highly efficacious therapies. JAMA1984; 251: 3387.
MartucciM, FabbriniG, MannaV: Nicergoline versus co-dergocrine mesylate in elderly patients with mild to moderate cognitive deficits. In Ergot Alkaloids and Aging. Proceedings of an International Symposium, Rome, 1 October 1987 (Kugler J, Agnoli A, eds). Amsterdam: Excerpta Medica, 1988; pp 52–56.
16.
ZylbermanMR, FontanaM, DolceG: Effects of nicergoline on learning mood and behaviour in hemiplegic patients undergoing rehabilitantion. In: Ergot Aklaloids and Aging. Proceedings of an International Symposium, Rome, 1 October. (KuglerJ, AgnoliA, eds). Amsterdam: Excerpta Medica, 1988; pp 57–63.
17.
ShaderRI, HarmatzJ, SalzmanC: A new scale for clinical assessment in geriatric populations. J Am Geriatr Soc1974; 22: 107–113.
18.
MogliaA, BattagliaA, BergonzoliS: Nicergoline versus placebo in patients with senile dementia, results of various methodological approaches. In: Ergot Alkaloids and Aging. Proceedings of an International Symposium, Rome, 1 October 1987 (KuglerJ, AgnoliA, eds). Amsterdam: Excerpta Medica, 1988; pp 36–42.
19.
FranchampsA: Dihydroergotoxin in senile cerebral insufficiency. In: Aging Brain and Ergot Alkaloids. Vol 23 (AgnoliA, CrepaldiG, SpanoPF, TrabucchiM, eds). New York: Raven Press, 1983; pp 311–322.
20.
SingerJH, HamotHBM, PatinJR: Differential patient responses to ergoloid mesylates according to current etiopathic notions of dementia. In: Aging 2000: Our Health Care Destiny. Vol 1: Biomedical Issues (GaitzCM, SamorajskiT, eds). New York: Springer Verlag, 1985; pp 405–420.
21.
BattagliaA, BruniG, ArdiaA: Nicergoline in mild to moderate dementia, J Am Geriatr Soc1989; 37: 295–302.
22.
BattagliaA: Nicergoline in mild to moderate dementia. A multicenter double-blind, placebo controlled study. JAGS1989; 37: 295–302.
23.
HollisterLE, YesavageJ: Ergoloid mesylates for senile dementias: Unanswered questions. Ann Intern Med1984; 100: 894.
24.
ChierchettiS, CucinottoD, SantiniV: Implications of long term study of hydergine in elderly patients with chronic senile cerebral insufficiency. In: Aging 2000: Our Health Care Destiny. Vol 1: Biomedical Issues (GaitzCM, SamorajskiP, eds). New York: Springer Verlag, 1985; 377–393.
25.
ThienhausOJ, WheelerBG, SimonS: A controlled double blind study of high dose dihydroergotoxine mesylate (hydergine) in mild dementia. J Am Geriatr Soc1987; 35: 219–223.
26.
Van Loren-HuybenCMS, EngerlaarHFWJ, HermansMBM: Double blind clinical and psychological study of ergoloid mesylate in subjects with senile mental deterioration. J Am Geriatr Soc1984; 32: 584–588.
27.
YesavageJM, LeirerV, BeckerL, HolmanC: Effect of an ergot preparation on cognitive ability and depression. J Psychiatr Treat Eval1981; 3: 153–156.
28.
OswaldWD, LangE: Therapeutische Beeinflussung von Leistung und Selbstbild bei geriatrischen Patienten. Munsch Med Mschr1980; 122: 59–62.
29.
OswaldWD, MatejcekKM, LukaschekK: Uber die Relevanz psychometrisch operationalisierter Therapie-Effekte bei der Behandlung altersbedingter Insuffizienerscheinungen des Gehirns. Arzneimittel Forschung1982; 35: 584–590.
30.
FarielloRG, CarfagnaN: Biological basis for synergism between pharmacological and behaviour intervention in the aging brain. Extended Abstract of Satellite symposium held during 2nd European Congress of Geronotology, Sept. 11 Madrid 1991Farmitalia Carlo Erba, Erbamount Group. Cordania, Milan, pp 34–42.
31.
SaletuB, GrunbergerJ: Memory dysfunction and vigilance, neurophysiological and neuropharmacological aspects. Ann NY Acad Sci1985; 444: 406–427.
32.
SaletuB, GrunbergerJ, LinzmayerL: Proof of CNS efficacy and pharmacodynamics of nicergoline in the elderly by psychometric study. In: Drug Treatment in Chronic Cerebrovascular Disorders (TognoniG, GarattiniS, eds). Amsterdam: Biomedical Press, Elsevier1979; 245–275.
33.
GessnerB, BauerW, ThomalskeG: Wirkungsnachweis vor Nicergoline bei geriatrischen Personen mittels biometrischer and quantitative EEG untersuchungen Berich. Frankfurt: Battelle-Institute. 1979.
34.
ArrigoA, MogliaA, BorsottiL: A double blind placebo controlled crossover trial with nicergoline in patients with senile dementia. Int J Clin Pharmacol Res1982; II: 33–41.
35.
RoubicekJ, GeigerC, AbtK: An ergot alkaloid proportion (Hydergine) in geriatric therapy. J Am Geriatr Soc1972; 20: 222–229.
36.
KuglerJ, OswaldWD, HerzfeldU: Langzeittherapie altersbedingter Insuffizienzerscheinungen des Gehirns. Dtsch Med Wochenschr1978; 103: 456–462.
37.
GoodinD, SquiresKC, StarrA: Long latency event components of auditory evoked potential in dementia. Brain1978; 101: 635–648.
38.
BreezeRW, CoxS, Rodgers-CoxJ: Changes in P300 latency as a result of co-degocrine mesylate therapy in patients with senile dementia. Int J Geriat Psychiatry1988; 3: 263–266.
